Cancer Care Gets Cheaper: Revised MRPs for 1,364 Formulations Effective Now
NPPA caps trade margins on anti-cancer drugs, leading to massive price cuts and estimated annual savings of Rs 3,540 crore for patients.
In a major move to make life-saving treatment more affordable, the revised Maximum Retail Prices (MRPs) for 1,364 anti-cancer formulations have come into effect today. This decision follows a strategic intervention by the National Pharmaceutical Pricing Authority (NPPA), operating under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, to cap trade margins on 137 anti-cancer drugs.
The price revision is based on the recommendations provided by an Expert Committee established by the Directorate General of Health Services (DGHS) under the Ministry of Health & Family Welfare on October 17, 2026. This policy shift is viewed as a critical component of the government's broader strategy to enhance healthcare access for those battling cancer.
Massive Price Drops and Consumer Savings
The scale of the price reduction is significant. As of November 8, 2026, 85 pharmaceutical companies have reported the updated MRPs for 1,364 formulations, which cover 121 different drugs. The impact on the patient's pocket is expected to be substantial:
- Widespread Reductions: Out of the reported brands, 679 have slashed their prices by more than 50 per cent.
- Maximum Discount: The highest reported drop in MRP is a staggering 96.45 per cent.
- Overall Impact: It is estimated that these price cuts will result in annual savings of approximately Rs 3,540.38 crore for consumers.
How Patients Can Verify New Prices
To ensure transparency and prevent overcharging, the government has provided multiple channels for patients to verify the cost of their medication. Consumers are advised to check the revised MRP printed directly on the medicine packaging. Additionally, prices can be verified through the following digital platforms:
- Pharma Sahi Daam: A dedicated mobile application for price verification.
- Official Website: The NPPA website at nppa.gov.in.
Strict Compliance and Grievance Redressal
The government has made it clear that no hospital pharmacy or chemist is permitted to charge more than the revised MRP. To maintain strict adherence to these norms, all medical institutions, pharmacies, and retailers are mandated to prominently display the revised price lists on their physical premises and official websites.
If a consumer encounters overcharging or has any pricing-related complaints, they can take the following actions:
- Register a grievance via the Pharma Jan Samadhan portal.
- Contact the NPPA helpline at 1800-111-255.
Regulatory Framework and Future Adjustments
These regulatory provisions, enacted through notification SO 5690 (E) dated October 17, 2026, will remain in effect until further orders. While trade margins are now capped, the government has left a window for manufacturers; drug companies may still claim annual price adjustments under Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, provided the products strictly adhere to the 30 per cent trade margin threshold.
"TMR of non-scheduled anti-cancer medicines is an important step taken by the Government in its continued efforts to improve affordability and accessibility of essential anti-cancer medicines for cancer care," the Ministry stated.